Summary
Redirect | ||||
---|---|---|---|---|
|
In this study we performed a detailed imaging detailed imaging characterization (workflow below) of this model, details are provided in the attached standard operating procedures. Tumors in half of the mice were resected in the range 200-300 cmmm3 size; tumors in the other half were allowed to grow until it was necessary to euthanize them because of tumor size.
T2w MRI at 56 days post implant demonstrated a heterogenous tumor with an apparent central hemorrhage and the implant appears to have a defined capsule. On day 98 (post-implant) the tumor increased in size (618%) with very similar imaging characteristics as displayed on day 56.
In contrast, the regrowth following surgical resection of the primary xenograft (105 days post resection) is homogenous, but also appears to have a well-defined capsule.
PET/CT Characterization of the primary tumor: Baseline PET (SOP attached) were performed when tumor reached an approximate 200 mm3. Average SUVbw_max values (n=5) were calculated; [18F]FDG: 1.8 ± 0.2 and [18F]FLT: 2.8 ± 0.7.
The imaging characteristics of this model, which is available from the National Cancer Institute Patient-Derived Models Repository (https://pdmr.cancer.gov/), is highly favorable for preclinical research studies when used in conjunction with non-contrast T2 weighted MRI.
Acknowledgements
...
Frederick National Laboratory for Cancer Research – Special Thanks to Joseph D. Kalen, PhD, Lilia V. Ileva, MS, Lisa A Riffle, Nimit Patel, Keita Saito, PhD, Yvonne Evrard, PhD, Jessica Phillips, Simone Difilippantonio, PhD, Chelsea Sanders, Amy James, Lia Thang, Ulrike Wagner, Yanling Liu, PhD, John B. Freymann, and Justin Kirby.
Division of Cancer Therapeutics and Diagnosis/National Cancer Institute - James L. Tatum, MD, Paula M Jacobs, PhD, Melinda G. Hollingshead, DVM, and James H. Doroshow, MD
PixelMed Publishing – Special Thanks to David A. Clunie, MD
University of Arkansas for Medical Sciences – Special Thanks to Kirk E. Smith
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. Number HHSN261201500003I. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Localtab Group | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|